Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and ...

Anthony Dimeo; Head-Investor Relations; Amneal Pharmaceuticals Inc. Chirag Patel; President, Co-Chief Executive Officer, Co-Founder, Director; Amneal Pharmaceuticals Inc. Chintu Patel; Co-Chief ...

BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Friday reported a loss of $31.1 million in its fourth quarter. The Bridgewater, New Jersey-based ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will present at the Barclays 27th Annual Global Healthcare Conference on March, 12, 2025. Chirag Patel, Co-Chief ...

Barclays raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $11 from $10 and keeps an Overweight rating on the shares. The company’s Q4 beat, “strong” 2025 guidance and ...

Amneal expects full-year earnings in the range of 65 cents to 70 cents per share, with revenue in the range of $3 billion to $3.1 billion. Amneal shares have increased almost 6% since the ...

Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The company had revenue of $730.52 million for the quarter, compared to analyst estimates of ...

Reports Q4 revenue $731M, consensus $708.07M. “Amneal’s continued success in 2024 demonstrates our ability to drive sustainable growth through disciplined execution, continuous innovation ...